17 citations
,
January 1999 in “Journal of Molecular Structure” Finasteride's molecular and crystal structures help develop new drug formulations.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
January 2025 in “International Journal of Molecular Sciences” Fenugreek extract may help treat benign prostatic hyperplasia.
January 2006 in “Zhongguo yaofang” Qianliekang and liuweidihuangwan are cheaper for BPH treatment than finasteride and tamsulosin.
October 2022 in “Biomedicines” Finasteride in male rats causes liver and metabolic issues in their offspring.
28 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” Serenoa repens is not proven effective for hair loss and may delay prostate cancer detection.
9 citations
,
July 2011 in “Cytokine” Finasteride helps reduce lung inflammation and damage after trauma and infection.
2 citations
,
January 2016 in “Andrology” 21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
January 2009 in “Chinese Journal of Drug Application and Monitoring” Finasteride granules and tablets work the same in the body.
November 2011 in “ChemInform” January 2005 in “Journal of Investigative Medicine” Testosterone boosts physical performance, grip strength, and lean body mass in older men with low testosterone.
1 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
December 2025 in “Molecular Pharmaceutics” Combining tadalafil and finasteride improves their solubility and effectiveness.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
127 citations
,
May 2004 in “PubMed” Finasteride may help some male chronic pelvic pain patients, but more research needed.
January 2014 in “Revista del Hospital Juárez de México” Finasteride reduces bleeding during prostate surgery.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
June 2014 in “Reactions Weekly” Finasteride can cause muscle weakness and eye movement issues, even at low doses.
6 citations
,
November 2010 in “International Journal of Andrology” New oral testosterone formulations show potential for safer, effective hormone replacement in men with low testosterone.
January 2007 in “El Servicio de Difusión de la Creación Intelectual (National University of La Plata)” Combining D-004 and finasteride is more effective at reducing prostate enlargement than using either alone.
March 2024 in “The journal of sexual medicine” Finasteride's negative effects on brain tissue in male rats may be reversible after stopping the drug.
February 2024 in “Practical Diabetes” Spironolactone helps reduce hospital visits and death from heart issues, lowers blood pressure, but has unclear effects on heart failure with normal heart pump function and can cause high potassium and breast enlargement in men.
These medications for BPH have known risks and may have new side effects.
November 2020 in “International journal of pharmaceutical compounding” A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
March 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride treatment changes certain urine metabolites in male pattern baldness patients.